版本:
中国

BRIEF-Adamas announces results of Ease Lid 3

Sept 20 Adamas Pharmaceuticals Inc

* Announces results of Ease Lid 3, a pivotal trial of ADS 5102 for the treatment of Levodopa-induced Dyskinesia (lid) in parkinson's disease patients at the 4th world parkinson congress

* Adamas Pharmaceuticals Inc says trial met its primary endpoint

* Trial met its primary endpoint

* ADS-5102 was generally well tolerated

* Statistically significant reduction in off time (a key secondary endpoint) was observed Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐